title: Diabetes field cautiously upbeat despite possible setback for leading SGLT2 inhibitor.
authors: Dan
authors: D
authors: Jones
mesh_terms: D000818:Animals; D002273:Carcinogens; D018795:Device Approval; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D009369:Neoplasms / Q000139:chemically induced; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D002273:Carcinogens; D007004:Hypoglycemic Agents; C089180:SLC5A2 protein, human; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors